Similarly, in oncology, semaglutide reprograms tumor-associated macrophages via the GLP-1R/PPARG/ACSL1 pathway, promoting M1 polarization and suppressing tumor progression [79]. This evidence concerns the gene ACSL1 and neoplasm.